Cancer Center Support Grant 2018-2023

癌症中心支持补助金 2018-2023

• 批准号: 9926966
• 负责人: Eric R. Fearon
• 金额: $ 5万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-06-01 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9926966
• 关键词: Achievement; Address; Affect; Animal Model; Basic Science; Behavior; Behavioral; Behavioral Research; Bioinformatics; Biostatistics Shared Resource; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Patient; Cancer Survivor; Caring; Catchment Area; Cells; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Communities; Complement; Comprehensive Cancer Center; Computer Analysis; Decision Making; Development; Developmental Therapeutics Program; Diagnosis; Diet; Doctor of Philosophy; Drug Kinetics; Drug Screening; Early Diagnosis; Education; Education and Outreach; Environment; Epigenetic Process; Event; Faculty Recruitment; Financial Support; Flow Cytometry; Fostering; Foundations; Funding; Funding Mechanisms; Future Generations; Gene Expression; Genetic; Genomics; Germ-Line Mutation; Goals; Grant; Health Communication; Health behavior outcomes; Hematopoiesis; Hormonal; Image; Image Analysis; Immune; Immunologic Monitoring; Immunology; Improve Access; Institution; Journals; Knowledge; Leadership; Lesion; Life Style; Malignant Neoplasms; Manuscripts; Michigan; Mission; Molecular; NCI Center for Cancer Research; National Cancer Institute; Neoplasms; Nucleic Acids; Outcome; Pathogenesis; Patient-Focused Outcomes; Patients; Pharmacology; Phenotype; Plant Roots; Population; Population Sciences; Positioning Attribute; Prevention; Prevention approach; Prevention program; Program Development; Proteins; Proteomics; Provider; Publications; Publishing; Quality of Care; Recording of previous events; Research; Research Personnel; Resource Sharing; Risk; Risk Assessment; Risk Reduction; Role; Schools; Science; Signal Pathway; Signal Transduction; Somatic Mutation; Structure; Tissue imaging; Tissues; Training; Transgenic Animals; Translating; Translational Research; Treatment outcome; Universities; University of Michigan Comprehensive Cancer Center; Vision; anticancer research; base; cancer care; cancer epidemiology; cancer genetics; cancer health disparity; cancer prevention; cancer research center director; cancer risk; cancer therapy; cancer type; care delivery; career; cellular imaging; clinically significant; college; community center; imaging approach; implementation research; improved; innovation; interdisciplinary collaboration; irradiation; lifestyle factors; medical schools; member; microbial; molecular pathology; novel; novel strategies; optimal treatments; pre-clinical; predictive marker; programs; protein expression; recruit; research data dissemination; single cell analysis; success; survivorship; translational scientist; tumor microenvironment

PROJECT SUMMARY/ABSTRACT (OVERALL) The University of Michigan Comprehensive Cancer Center (UMCCC) has a distinguished history of scientific excellence, collaboration, and impact. Its mission is to reduce cancer burden and improve cancer outcomes through research, innovation, transdisciplinary collaboration, education, and outreach and engagement. The vision of the UMCCC is that through its focus on team science and research excellence, the UMCCC will be a national leader in prevention, early diagnosis, optimal treatment, and survivorship care for those at risk of or affected by cancer. Founded in 1986 as the matrix cancer center of the University of Michigan (U-M), the UMCCC first received National Cancer Institute (NCI) designation in 1988, and it has been a comprehensive cancer center since 1991. With strong support from the U-M leadership team and the UMCCC community, Eric Fearon, MD, PhD, was appointed as the third UMCCC Director in September 2016. Dr. Fearon has held multiple leadership roles in UMCCC throughout the past two decades, including Deputy Director, AD for Basic Sciences, and Program Co-Leader for Cancer Genetics. The Center provides an organizational framework to promote transdisciplinary cancer research through the development of well-funded basic, translational, clinical, and prevention programs and the development of shared resources. The Cancer Center’s seven research programs includes four basic programs – Cancer Biology, Cancer Genetics, Cancer Hematopoiesis and Immunology and Developmental Therapeutics; the Translational and Clinical Research Program; and two cancer control and population sciences programs – Health Behavior and Outcomes and Cancer Epidemiology and Prevention. UMCCC supports 11 Shared Resources and two developing Shared Resources: Biostatistics, Analytics and Bioinformatics; Cell and Tissue Imaging; Experimental Irradiation; Flow Cytometry; Health Communications; Immune Monitoring; Pharmacokinetics; Preclinical Imaging and Computational Analysis; Structure and Drug Screening; Tissue and Molecular Pathology; Transgenic Animal Models; Proteomics (developing); and Single Cell Analysis (developing). The UMCCC has 287 members representing 50 departments and eight schools and colleges across the University of Michigan. The UMCCC was ranked in the top 10 of NCI-funded academic institutions in 2016 and UMCCC members have annual direct funding of over $100 million. The scientific impact of UMCCC research is reflected through the roughly 4400 UMCCC member publications during the 2012-2016 period, including 15% of UMCCC manuscripts published in journals with impact factor >10, and the strong portfolio of cancer-focused grants held by our members. Fostering transdisciplinary collaboration is a key tenet of UMCCC, evidenced by a high degree of intra- (23.7%) and inter-programmatic publications (31.6%). The Medical School has made substantial commitments to UMCCC through space, financial support, and the recognition of cancer programs as a top priority for the institution.

项目摘要/摘要（总体） 密歇根大学综合癌症中心（UMCCC）具有杰出的科学史 卓越，协作和影响。它的使命是减少癌症伯恩并改善癌症结果 通过研究，创新，跨学科的合作，教育以及宣传与参与。这 UMCCC的愿景是，通过关注团队科学和研究卓越，UMCCC将成为一个 针对有或有风险或 受癌症的影响。成立于1986年，是密歇根大学（U-M）的基质癌症中心， UMCCC于1988年首次获得国家癌症研究所（NCI）的名称，这是一个全面的 自1991年以来，癌症中心。在U-M领导团队和UMCCC社区的大力支持下 2016年9月，医学博士Fearon，医学博士被任命为第三任UMCCC董事。 在过去的二十年中 科学和癌症遗传学的计划共同领导者。该中心为组织框架提供了 通过开发资金充足的基本，翻译，临床，促进跨学科的癌症研究 和预防计划以及共享资源的发展。癌症中心的七项研究 计划包括四个基本计划 - 癌症生物学，癌症遗传学，癌症造血和 免疫学和发育治疗学；翻译和临床研究计划；和两个 癌症控制和人口科学计划 - 健康行为和结果以及癌症流行病学 和预防。 UMCCC支持11个共享资源和两个开发的共享资源：生物统计学， 分析和生物信息学；细胞和组织成像；实验辐照；流式细胞仪；健康 通讯；免疫监测；药代动力学；临床前成像和计算分析； 结构和药物筛查；组织和分子病理；转基因动物模型；蛋白质组学 （发展）;和单细胞分析（开发）。 UMCCC有287名代表50名成员 密歇根大学的系和八所学校和学院。 UMCCC在 NCI资助的学术机构在2016年和UMCCC成员的年度直接资助 1亿美元。 UMCCC研究的科学影响反映了大约4400个UMCCC成员 2012 - 2016年期间的出版物，其中包括在期刊上发表的15％的UMCCC手稿 影响因子> 10，以及我们成员持有的以癌症为中心的赠款的强大投资组合。寄养 跨学科合作是UMCCC的关键宗旨，以高度的内部（23.7％）和 截面间出版物（31.6％）。医学院已对UMCCC做出了重大承诺 通过太空，财政支持以及对癌症计划的认可，作为该机构的重中之重。